Mr. Zheng Liang
General Manager
Taizhou Jingshang Cosmetics Technology Co., Ltd.
888 South Huanzhen Road
Hengie Town
Luqiao Qu
Taizhou Shi
Zhejiang Sheng , 318050FEI 3014244255Issued Apr 2, 2025Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3014244255.
Violations4
Issue DateApr 2, 2025
Product TypeDrugs
StatusOpen
Letter Details
Firm
Taizhou Jingshang Cosmetics Technology Co., Ltd.
Location
Mr. Zheng Liang
General Manager
Taizhou Jingshang Cosmetics Technology Co., Ltd.
888 South Huanzhen Road
Hengie Town
Luqiao Qu
Taizhou Shi
Zhejiang Sheng , 318050
FEI Number
3014244255
Country
China
Issue Date
April 02, 2025
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Summary
Taizhou Jingshang Cosmetics Technology Co., Ltd., a drug manufacturer in China, was cited for significant Current Good Manufacturing Practice (CGMP) violations in the production of over-the-counter drug products. The company failed to conduct identity testing on incoming components and did not validate supplier test analyses at appropriate intervals, accepting certificates of analysis without verification. Additionally, the firm failed to adequately test incoming active pharmaceutical ingredients for required specifications. The FDA issued this warning letter after an inspection in November 2024 and noted that no response had been received from the company addressing the Form FDA 483 deficiencies.
Taizhou Jingshang Cosmetics Technology Co., Ltd. FDA Warning Letter, April 2, 2025
Talk to a Specialist